Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTAWWS1632

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	FEB 27	New STN AnaVist pricing effective March 1, 2006
NEWS 4	APR 04	STN AnaVist $500 visualization usage credit offered
NEWS 5	MAY 10	CA/CAplus enhanced with 1900-1906 U.S. patent records
NEWS 6	MAY 11	KOREAPAT updates resume
NEWS 7	MAY 19	Derwent World Patents Index to be reloaded and enhanced
NEWS 8	MAY 30	IPC 8 Rolled-up Core codes added to CA/CAplus and USPATFULL/USPAT2
NEWS 9	MAY 30	The F-Term thesaurus is now available in CA/CAplus
NEWS 10	JUN 02	The first reclassification of IPC codes now complete in INPADOC
NEWS 11	JUN 26	TULSA/TULSA2 reloaded and enhanced with new search and and display fields
NEWS 12	JUN 28	Price changes in full-text patent databases EPFULL and PCTFULL

NEWS EXPRESS FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.
V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT
http://download.cas.org/express/v8.0-Discover/

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8
NEWS X25	X.25 communication option no longer available after June 2006

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 11:12:40 ON 30 JUN 2006

=> FILE MEDLINE,CAPLUS,BIOSIS, EMBASE, SCISEARCH

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	1.05	1.05

FILE 'MEDLINE' ENTERED AT 11:15:49 ON 30 JUN 2006

FILE 'CAPLUS' ENTERED AT 11:15:49 ON 30 JUN 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

```
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 11:15:49 ON 30 JUN 2006
Copyright (c) 2006 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 11:15:49 ON 30 JUN 2006
Copyright (c) 2006 Elsevier B.V. All rights reserved.

FILE 'SCISEARCH' ENTERED AT 11:15:49 ON 30 JUN 2006
Copyright (c) 2006 The Thomson Corporation

=> S gp100
L1         2809 GP100

=> S avipox
L2          338 AVIPOX

=> S poxvirus
L3        11228 POXVIRUS

=> L1 AND L2 AND L3
L1 IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> S L1 AND L2 AND L3
L4            0 L1 AND L2 AND L3

=> S L1 AND L2
L5            0 L1 AND L2

=> S "T cell activating cytokine"
L6           43 "T CELL ACTIVATING CYTOKINE"

=> S L1 AND L6
L7            1 L1 AND L6

=> S L2 AND L6
L8            0 L2 AND L6

=> S L3 AND L6
L9            0 L3 AND L6

=> S T cell activating cytokine
L10          43 T CELL ACTIVATING CYTOKINE

=> S gene therapy
L11      162287 GENE THERAPY

=> S L1 AND L11
L12         125 L1 AND L11

=> S L6 AND L12
L13           0 L6 AND L12

=> S cytokine
L14      737027 CYTOKINE

=> S L14 AND L11 AND L1
L15          33 L14 AND L11 AND L1

=> S L14 AND L11 AND L1 AND L3
L16           1 L14 AND L11 AND L1 AND L3
```

=> D L15

L15 ANSWER 1 OF 33 MEDLINE on STN
AN 2005219788 MEDLINE
DN PubMed ID: 15853729
TI Cancer gene therapy utilizing interleukin-13 receptor alpha2 chain.
AU Kawakami Koji
CS Laboratory of Molecular Tumor Biology, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD, USA.. kawakami-k@umin.ac.jp
SO Current gene therapy, (2005 Apr) Vol. 5, No. 2, pp. 213-23. Ref: 123
Journal code: 101125446. ISSN: 1566-5232.
CY Netherlands
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
LA English
FS Priority Journals
EM 200506
ED Entered STN: 29 Apr 2005
Last Updated on STN: 1 Jul 2005
Entered Medline: 30 Jun 2005

=> D ti,abs L15 1-33

L15 ANSWER 1 OF 33 MEDLINE on STN
TI Cancer gene therapy utilizing interleukin-13 receptor alpha2 chain.
AB Cancer cells are known to express cell surface molecules such as specific antigens or cytokine receptors, e.g., EGFR, Fas/CD95, gp100, HER-2/neu, IL-13Ralpha2, and MAGE. Among them, interleukin-13 receptor (IL-13R) alpha2 chain is expressed on certain types of cancer cells including glioblastoma, AIDS Kaposi's sarcoma, and head and neck cancer. This protein is one of the receptor components for IL-13, a Th2 cell-derived pleiotropic immune regulatory cytokine . IL-13Ralpha2 chain on these cancer cells can be targeted with a receptor-directed cytotoxin termed IL13-PE to induce specific cancer cell killing, however, this molecule does not mediate cytotoxicity to cells that do not express or express low levels of IL-13Ralpha2. In order to achieve a broad therapeutic window for IL13-PE, plasmid-mediated gene transfer of IL-13Ralpha2 in cancer cells was employed in vitro and in vivo. Cancer cells transfected with IL-13Ralpha2 demonstrated increased binding to IL-13 and sensitivity to IL13-PE in vitro. In vivo intratumoral gene transfer of IL-13Ralpha2 profoundly enhanced the antitumor activity of IL13-PE, providing complete elimination of established tumor in some xenografts. In this review article, current findings from IL-13Ralpha2 gene transfer in a variety of human cancer models in nude mice are summarized. In addition, safety issues and possible future directions utilizing this therapeutic approach are discussed.

L15 ANSWER 2 OF 33 MEDLINE on STN
TI Biased epitope selection by recombinant vaccinia-virus (rVV)-infected mature or immature dendritic cells.
AB Recombinant expression vectors represent a powerful way to deliver whole antigens (Ags) for immunization. Sustained Ag expression in vector-infected dendritic cells (DC) combines Ag-specific stimulation with powerful costimulation and, simultaneously, through 'self-selection' of ad hoc epitopes broadens the scope of immunization beyond restrictions posed by individual patients' human leukocyte antigen (HLA) phenotype. In this study, therefore, we evaluated the efficiency of a recombinant vaccinia virus encoding the gp100/PMel17 melanoma Ag (rVV-gp100) to infect immature (iDC) or mature dendritic cells (mDC) derived from